Kornimate/medical-research-clean huggingface dataset:
clinical relevance of different training intensities in chronic heart failure.

Conditions: Chronic Heart Failure

Summary: to determine the efficacy of different aerobic exercise training intensities in patients with chronic heart failure.forty five eligible male patients with chronic heart failure were randomly assigned into three groups( high intensity , moderate intensity and low intensity)groups .

forty five eligible male patients with chronic heart failure secondary to ischemic heart disease were selected from national heart institute heart failure outpatient clinic , their ages ranged from 50-60 years old and their ejection fraction ranged from 30-40% ,they were randomly assigned into three groups :hit group: received high intensity aerobic training in the form of bicycle ergometer exercise for the lower limbs three times /week for three months.(n=15) mit group: received moderate intensity aerobic training in the form of bicycle ergometer exercise for the lower limbs three times /week for three months. .(n=15) lit group: received low intensity aerobic training in the form of bicycle ergometer exercise for the lower limbs three times /week for three months, before and after intervention, the following measures were obtained: echocardiograph parameter (ef%, and left ventricular internal dimension ) , prognostic biomarkers (probnp), and quality of life .

Eligibility criteria:
inclusion criteria: * patients with following criteria were included : * all patients ages were between 50 - 60 years old * fractional shortening \< 25% and ejection fraction \< 40% * sinus rhythm. * heart failure due to ischemic heart disease. * new york heart association (nyha) class ii-iii. * regular medical treatment. exclusion criteria: * patients with following criteria were excluded : * chronic heart failure due to other causes * history of pulmonary disease (chronic obstructive lung disease, moderate to severe pulmonary hypertension). * recent acute coronary syndrome or revascularization (3 months). * exercise limited by angina or peripheral arterial occlusive disease; * cerebrovascular or musculoskeletal disease preventing exercise testing or training. * poorly controlled or exercise-induced cardiac arrhythmias * logistic problems to attend regular exercise training sessions. uncontrolled hypertension.
recurrent persistent atrial fibrillation:in-situ ablation vs extensive ablation

Conditions: Recurrent Persistent Atrial Fibrillation

Summary: this is an open label, randomized parallel control clinical trial, to compare extra-pv extensive ablation with in-situ ablation as two strategies for the treatment of peraf to identify the mechanisms of peraf recurrence.

this is an open label, randomized parallel control clinical trial. patients with recurrent persistent atrial fibrillation are 1:1 randomized into ext group(extra-pv extensive ablation) and in-situ group(repeat same pvi and linear ablation as the first procedure). postoperative recurrence rate and other indicators are analyzed to compare extra-pv extensive ablation with in-situ ablation as two strategies for the treatment of peraf to identify the mechanisms of peraf recurrence.

Eligibility criteria:
inclusion criteria: 1. age 18 years or older; 2) diagnosed as recurrent peraf according to the latest clinical guidelines; 3) ineffective or intolerable to ≥1 anti-arrhythmia drug treatment; 4) the first ablation procedure was pvi and linear ablation; 5) consented to receive radiofrequency catheter ablation. exclusion criteria: * 1) recurrent atrial flutter/atrial tachycardia; 2) the first ablation procedure included extra-pv substrate ablation; 3) the first low voltage area\>30%; 4) serious complications during the first procedure; 5) the first ablation was paroxysmal atrial fibrillation. 6) uncontrolled congestive heart failure; 7) history of severe valve disease and/or prosthetic valve replacement; 8) left atrial thrombus confirmed by preoperative esophageal ultrasound; 9) severe congenital heart disease; 10) severe lung disease; 11) left atrial diameter ≥60mm; 12) contraindications for cardiac catheterization; 13) myocardial infarction or stroke within 6 months; 14) contrast agent allergy; 15) the use of anticoagulant drugs is contraindicated; 16) have performed any cardiac surgery within 2 months;17) life expectancy is less than one year, including factors such as physical inability to tolerate ablation or unstable disease conditions.
ceramenttm|g and v in the management of hip and knee arthroplasty revisions (revision arthroplasty italy)

Conditions: Hip Prosthesis Infection; Knee Prosthesis Infection

Summary: open-label, multicentre, prospective cohort, observational clinical trial with a retrospective control group to evaluate the effectiveness and safety of ceramenttm\| g or v used for filling of bone defects in the tibia and / or femur shaft and/or acetabulum in patients scheduled for two-stage hip or knee prosthesis re-implantation for pji or aseptic loosening. the results will be compared to a cohort of patients, which have been treated before the introduction of ceramenttm\|g or v for the same indication. due to the observational character of the study, there will be no patient randomization and the clinicians in the study will remain entirely free to decide on the treatment of the patients according to established clinical practice. only patients for whom therapeutic strategy for the use of the product for filling bone defects is already planned according to local clinical practice, at the time of informed consent form signature, will be enrolled in this study. thus, the decision for the choice of the surgical treatment, will not be influenced by the inclusion of the patient in this study.


Eligibility criteria:
inclusion criteria: 1. written informed consent obtained prior to any study related procedure. 2. male or female age ≥ 18 and ≤ 85 years. 3. patients diagnosed with aseptic prosthetic loosening and scheduled for a one-stage hip or knee cementless or hybrid revision prosthesis implantation 4. patients with an interval spacer and scheduled for hip or knee cementless or hybrid revision prosthesis implantation. 5. for those patients with an interval spacer, previous infection caused by microorganism(s) sensitive to gentamicin or vancomycin. 6. able (in the investigators opinion) and willing to comply with all study requirements exclusion criteria: 1. unable to give written informed consent. 2. medically unfit for operative intervention. 3. soft-tissue defects that prevent direct skin closure at revision surgery. 4. females who are pregnant or lactating. 5. females of child bearing potential and not taking adequate contraceptive precautions are excluded from the trial. females of child bearing potential taking acceptable contraceptive precautions may be included. 6. known allergy to gentamicin or vancomycin (or related antibiotics). 7. patients with previous nephro- or ototoxicity events due to aminoglycoside and/or vancomycin (or glycopeptides) use. 8. presence of relevant contraindications as described in the eu ce mark instructions for use (ifu). 9. myasthenia gravis. 10. need of a fully cemented joint prosthesis. 11. psychiatric or neurological disorders. 12. active infection at the site of surgery as diagnosed by clinical and/or laboratory and/or imaging investigations. -
pms study of amlodipine/valsartan for the treatment of hypertension

Conditions: Essential Hypertension

Summary: the antihypertensive effect of amlodipine/valsartan combination has been evaluated in worldwide populations including asian patients. the study primarily aims to evaluate the effectiveness of amlodipine/valsartan combination in patients with essential hypertension in taiwan using a prospective, open-label, non-randomized approach. the study also wants to investigate the safety of amlodipine/valsartan combination during the 6-week treatment period.


Eligibility criteria:
inclusion criteria: * patients who are 20-80 years of age * patients with essential hypertension (90 mmhg ≤ dbp ≤ 110 mmhg and/or 140 mmhg ≤ sbp ≤ 180 mmhg) whose bp is not adequately controlled with amlodipine (or another ccb) alone or with valsartan (or another arb) alone, or with any antihypertensive monotherapy. * agree to and are able to follow the study procedures * understand the nature of the study, and have signed informed consent forms exclusion criteria: * patients with any of the following conditions: 1. malignant (or history of malignant) hypertension 2. secondary hypertension 3. severe hypertension (mean sitting dbp ≥ 110 mmhg and/or mean sitting sbp ≥ 180 mmhg) 4. a history of hypertensive encephalopathy or cerebrovascular accident 5. cerebrovascular accident, myocardial infraction within 3 months, or any type of revascularization 6. new york heart association class iii -iv congestive heart failure 7. second- or third-degree heart block 8. angina pectoris 9. significant arrhythmia or valvular heart disease 10. significant pancreatic, hepatic, or renal disease 11. diabetes requiring insulin treatment or poorly controlled type 2 diabetes * patients with known contraindication or a history of allergy to ccbs or arbs. * female patients who are pregnant or lactating. * male or female patients of child-bearing potential who do not agree to use an effective method of contraception during the study * patients is currently participating in any other clinical trial within 30 days
the effects of different doses of dexmedetomidine on propofol requirement for loss of consciousness undergoing bispectral index: a double-blinded, placebo-controlled trial

Conditions: Loss of Consciousness

Summary: the purpose of this study is to evaluate the effects of different dexmedetomidine on the propofol requirement for loss of consciousness undergoing bispectral index.

it has been shown that dexmedetomidine was an efficacious and safe adjuvant in general anaesthesia. administration of dexmedetomidine during the preoperative period has been demonstrated to reduce the requirement of opioid analgesics and other sedative and hypnotic drugs.therefore, the study is designed to measure the effect of intravenous dexmedetomidine premedication on the propofol dose requirement and bispectral index at loss of consciousness.

Eligibility criteria:
inclusion criteria: * asa physical status i-ii * aged 18-65 years * body mass index 18.0～24.5 kg/m2 * without hearing impairment exclusion criteria: * bradycardia * atrioventricular block * neurologic disorder and recent use of psychoactive medication * allergic to the drugs

Keywords: propofol dexmedetomidine dose bispectral index monitor
efficacy and safety of cladribine combined with beac pretreatment regimen in the treatment of peripheral t-cell lymphoma: a multicenter clinical study

Conditions: Peripheral T-cell Lymphoma

Summary: this multi-center clinical study will evaluate the efficacy and safety of cladribine combined with beac pretreatment regimen in the treatment of peripheral t-cell lymphoma.

peripheral t-cell lymphomas (ptcl) is a group of highly heterogeneous aggressive non-hodgkin lymphomas originating from mature post-thymic t lymphocytes or nk/t cells. the treatment effect of patients receiving autologous hematopoietic stem cell transplantation (asct) is better than traditional chemotherapy, but the recurrence after transplantation is still as high as 50%. it is an urgent clinical problem to reduce the recurrence after ptcl transplantation. cladribine can kill quiescent tumor cells, which is the main reason of tumor recurrence. since 2018, our center has used cladribine combined with beac pretreatment regimen to treat 20 patients with ptcl. the pfs reached 68% at 2 years, which is about 15% higher than the previous classic beac regimen. this multi-center clinical study will further evaluate the efficacy and safety of cladribine combined with beac pretreatment regimen in the treatment of peripheral t-cell lymphoma.

Eligibility criteria:
inclusion criteria: * 18-65 years old, no gender limit; * ecog 0-2, estimated survival time ≥ 3 months; * pathologically newly diagnosed with ptcl (except alk+ anaplastic large cell lymphoma), with pr or cr after 6 cycles of induction chemotherapy; * hb≥80g/l, anc≥1.0×10\^9/l, plt≥75×10\^9/l; tbil≤1.5×uln, alt/ast≤2.0× uln, cr ≤1.5×uln in the 14 days before enrollment * have not received hematopoietic stem cell transplantation and other treatments within 4 weeks before enrollment; * the number of hematopoietic stem cells requires mnc ≥3×10\^8/kg and/or cd34 cells ≥2×10\^6/kg; * informed consented exclusion criteria: * accompanied by severe cardiac insufficiency, cardiac ejection fraction \<60%; or severe arrhythmia, intolerance of pretreatment; * accompanied by severe pulmonary insufficiency (obstructive and or restrictive ventilatory disorders), intolerance of pretreatment; * accompanied by severe liver function impairment, liver function indexes (alt, tbil) are more than 3 times higher than the upper limit of normal, intolerance of pretreatment; * accompanied by severe renal insufficiency, the renal function index (cr) is more than 2 times the upper limit of normal; or the 24-hour urine creatinine clearance rate ccr is less than 50ml/min, intolerance of pretreatment; * severe active infection before transplantation, intolerance of pretreatment; * accompanied by brain dysfunction or severe mental illness, unable to understand or follow the research plan; * pregnant or lactation； * accompanied by other malignant tumors in need of treatment; * patients who cannot guarantee the completion of the necessary treatment plan and follow-up observation.

Keywords: peripheral t-cell lymphoma autologous stem cell transplantation cladribine beac
effects of canola oil and coconut oil on postprandial metabolism in older adults with increased cardiometabolic risk

Conditions: Cardiovascular Diseases; Metabolic Syndrome

Summary: the aim of this study is to investigate the postprandial effects of fat content and fatty acid composition of mixed meals on parameters associated with cardiometabolic diseases. therefore, older subjects with increased risk of cardiometabolic diseases consume 4 mixed meals with 25 or 50 g of either canola or coconut oil. in a postprandial period of 6 hours, outcomes associated with cardiometabolic risk (e.g., triglycerides) are analyzed.

in a crossover design, 30 older men and women with increased risk of cardiometabolic diseases consume 4 mixed meals, enriched with either 25 or 50 g canola or coconut oil. during a postprandial period of 6 hours, parameters of lipid metabolism (e.g., plasma triglycerides), glucose metabolism (e.g., plasma glucose, serum insulin), as well as markers of inflammation (e.g., il-6), vascular system (e.g., pulse wave velocity) and antioxidant system (e.g., trolox equivalent antioxidative capacity) are analyzed. furthermore, fatty acid profile, neuropsychologic parameters (e.g., attention), subjective feeling of hunger and satiety, and satiety-associated hormones (e.g., ghrelin) are assessed. each intervention arm will be separated by a washout period of about 14 days.

Eligibility criteria:
inclusion criteria: * bmi: 27 - 34,9 kg/m2 * waist circumference: women ≥ 80 cm, men ≥ 94 cm * at least two of the following criteria of metabolic syndrome: fasting triglycerides in serum: ≥ 150 mg/dl fasting hdl-cholesterol in serum: women \< 50 mg/dl, men \< 40 mg/dl systolic blood pressure: ≥ 130 mmhg, diastolic blood pressure: ≥ 85 mmhg fasting glucose in plasma: ≥ 100 mg/dl exclusion criteria: * smoking * diseases that may impact outcome measures (e.g., thyroid diseases, insulin-dependent diabetes mellitus, impaired renal function, tumors, anemia) * intake of immunosuppressives or supplements (e.g., fish oil) * participation in another study

Keywords: postprandial metabolic events
anterior vs posterior surgery for lumbar isthmic spondylolisthesis

Conditions: Isthmic Spondylolisthesis

Summary: currently there is no consensus on the best surgical treatment of patients with symptomatic isthmic spondylolisthesis (is). clinical equipoise exists amongst experienced clinicians on the various surgical techniques available. this study will involve multiple phases to answer specific research questions comparing anterior and posterior interbody fusion in patients with lumbar isthmic spondylolisthesis. the primary end point will be 1-year proportions of patients reaching minimal clinically important difference (mcid) in terms of leg pain measured by nrs leg. the secondary endpoints will be predetermined moderate to severe aes, reoperations for nonunion, symptomatic adjacent segment disease, radiological alignment correction and correlation with hrqol as well as economic analysis at 1, 2, 5 and 10 years.


Eligibility criteria:
inclusion criteria: * male or female aged 18 years or older (or who have reached the age of majority in the participating province) * require surgical treatment for a diagnosis of single-level lumbar isthmic spondylolisthesis, any grade, in the lumbar and lumbosacral spine. * are able to communicate in english or french * anterior interbody fusion group will be defined as having had an anterior or oblique approach with a synthetic cage insertion, interbody bone graft without cage or plate-screw construct with or without posterior rod-screw construct * posterior interbody fusion group will have only posterior approach procedure. exclusion criteria: * previous spinal surgery * specific pathology at level above and below: * degenerative anterolisthesis * pars defect above or below index level
lung lavage with dilute poractant alfa for meconium aspiration syndrome

Conditions: Meconium Aspiration Syndrome

Summary: meconium aspiration syndrome (mas) is an important cause of severe respiratory failure in newborn infants. treatment for mas is mainly supportive but surfactant therapy might change the course of the disease. aim of the study to evaluate whether lung lavage with dilute or bolus poractant alfa changes the duration of mechanical respiratory support or other outcomes in mas.


Eligibility criteria:
inclusion criteria: * infants with a gestational age ≥ 36 weeks, birth weight ≥ 2.0 kg, evidence of passage of meconium at or before delivery, typical chest radiology findings and mechanically ventilated infants with a mean airway pressure ≥ 12 cm h2o were enrolled. exclusion criteria: * congenital cardiac anomalies * major congenital anomalies * hemodynamically unstable infants

Keywords: lung lavage, surfactant, duration of mechanical ventilation
mri substudy; metabolic changes due to iatrogenic hypogonadism

Conditions: Prostate Cancer; Metabolic Syndrome; Hypogonadism; Fatty Liver

Summary: the purpose of this study is to investigate if androgen deprivation therapy in men with prostate cancer increases hepatic fat content and changes visceral/subcutaneous fat distribution.

this is a substudy of the ongoing randomized trial entitled: metabolic changes due to iatrogenic hypogonadism in patients with prostate cancer: orchiectomy vs. triptorelin (eudract number: 2013-002553-29). 20 consecutive patients are anticipated to participate regardless of assignment to either orchiectomy or triptorelin.

Eligibility criteria:
inclusion criteria: * eligible for inclusion are patients who are included in the already ongoing randomised trial entitled: metabolic changes due to iatrogenic hypogonadism in patients with prostate cancer: orchiectomy vs. triptorelin (eudract number: 2013-002553-29) exclusion criteria: * implanted devices or foreign metallic bodies incompatible with magnetic resonance imaging. * claustrophobia * severe psychiatric disease
effects of naturalistic decision-making model-based oncofertility care education

Conditions: Fertility Issues; Breast Cancer; Education

Summary: his study examined the effects of an oncofertility education program on decisional conflict in nurses caring for breast cancer patients and patients with breast cancer. other predictors of decisional conflict were also examined.

background: nurses play an essential role in transferring knowledge to patients. however, several factors cause nurses to adopt a negative attitude toward providing oncofertility care. objective: this study examined the effects of an oncofertility education program on decisional conflict in nurses caring for breast cancer patients and patients with breast cancer. other predictors of decisional conflict were also examined. design: randomized, controlled experimental research. settings and participants: patients (61) with breast cancer and nurses (79) were recruited from a hospital in taipei, taiwan. methods: the nursing participants were randomly assigned to receive oncofertility education (experimental group) or usual education (control group). data from female patients in the control and experimental groups were collected before and after the nurses' educational training, respectively. the oncofertility education consisted of one face-to-face educational session and reading one educational booklet based on the naturalistic decision-making (ndm) model. the decisional conﬂict was measured using the chinese version of the decisional conﬂict scale.

Eligibility criteria:
inclusion criteria: * all nurses involved in breast care were recruited into the study. * female patients with breast cancer who were younger than 50 years and who were about to start cancer treatment were recruited from one teaching hospital in taipei, taiwan. exclusion criteria: * women with a major illness or mental disorder before their cancer diagnosis were excluded.

Keywords: education decisional conflict breast cancer nurse oncofertility
skip prep of vaginal delivery to prevent puerperal / perinatal infection in vaginal delivery

Conditions: Vaginal Delivery; Surgical Site Infection

Summary: this is a multi-center, randomized, controlled trial study to find whether use of chlorhexidine-alcohol or povidone-iodine for pre-vaginal delivery skin prep is superior to reduce postpartum infection in pregnant women with vaginal delivery. the primary outcome is the episiotomy site infection.


Eligibility criteria:
inclusion criteria: * women with singleton pregnancy * women who will undergo vaginal delivery after 37+0/7 weeks of gestation exclusion criteria: * women who are allergy to chlorhexidine, alcohol, iodine, or shellfish * women with any infection at perineum (before vaginal delivery)

Keywords: chlorhexidine-alcohol povidone-iodine perineal infection surgical site infection
characteristics of long covid-19 syndrome

Conditions: Long COVID Syndrome

Summary: characterization of patients with long covid syndrome including symptoms, medical history and persistent organ damage.

some people are very hesitant to recover from a covid-19 infection and present persistent symptoms. the participants still suffer after the acute phase of the infection from shortness of breath, coughing, chest pain or fatigue. therefore, a special interdisciplinary consultation was built. the consulatation is not only addressed to people who have been hospitalized due to covid-19, but also to those with mild symptoms during infection. during the consultation hours, personal health data are collected that serves as the basis for this research project.

Eligibility criteria:
inclusion criteria: * long covid syndrome * age \>= 18 years * informed consent exclusion criteria: * none

Keywords: long covid post covid